Please ensure Javascript is enabled for purposes of website accessibility
Cabot Prime Pro Logo
Cabot Prime Pro

Weekly Summary December 13, 2019

Cabot Prime Pro Week Ending December 13, 2019

Stock Recommendation Tracker

The Stock Recommendation Tracker is a table that features all of the current recommendations in all of our portfolios. It’s a quick way for you to see what stocks are currently in our portfolios and will highlight new additions or any changes to our recommendations over the previous week. We include this table at the bottom of the Weekly Summary, and provide a link here at the top to the Stock Recommendations Tracker.

Cabot Weekly Review (Video)

In this week’s stock market video, Tyler Laundon highlights three conservative growth stocks that should do well in 2020 and could make great gifts for anybody on your shopping list. Highlights of the names include strong recurring revenue and consistent profitability.

CABOT EVENTS:

2020 Market Outlook + 3 Stocks to Buy Now

FREE WEBINAR: Thursday, January 23

By Mike Cintolo, Chief Analyst of Cabot Growth Investor and Cabot Top Ten Trader | Space is limited so sign up now for FREE.
SAVE THE DATE

2020 Cabot Wealth Summit - August 19-21, 2020

Click Here for More Information.

Advisory Services

Cabot Growth Investor

Bi-weekly Update December 12: Remain bullish, while keep your eyes open as some stocks have hit potholes. The market itself is in good shape, though Mike continues to think some news-driven ups and downs are likely in the near term. Individual stocks have turned mixed of late, and he’s keeping his eyes peeled for abnormal action. Tonight, he’s placing Dexcom (DXCM) on Hold due to its recent weakness, but have no other changes. Our cash position is around 24%.

Special Bulletin December 10: The market remains in a normal consolidation phase, and most of our stocks look fine. That said, today, Mike is selling MasTec (MTZ) which has been unable to get off its knees since its unusual decline a couple of weeks back. He’ll sell and hold the cash for now.

Bi-weekly Issue December 5: The market has finally begun to consolidate after a heady eight-week run in the major indexes and leading stocks. It’s never fun to see things retrench, and Mike does think the next couple of weeks (very roughly speaking) could see more choppy, tedious trading. But his focus remains on the intermediate- and longer-term picture, and on that front, the evidence remains bullish, so he remains heavily invested. The Model Portfolio has been steadily putting money to work, including filling out two positions last week. We now have eight stocks and a cash position of around 14%. In tonight’s issue, Mike gives his latest thoughts on all our positions and writes about yet another unique, longer-term bullish occurrence that bodes well going forward.

Other Stocks of Interest November 21: Follow ups to stocks featured July 3, 2019 (issue 1423) to November 21, 2019 (issue 1433). Since many of the stocks written about in Other Stocks of Interest don’t make their way into the Model Portfolio, you won’t see them followed on a regular basis in the issues. However, we are monitoring these stocks, and this listing gives you a quick view of our latest thoughts. Feel free to email me directly (mike@cabotwealth.com) with any questions/comments you have.

Cabot Top Ten Trader

Movers & Shakers December 13: All in all, Mike remains bullish, and ideally, the news flow will subside somewhat and stocks can get back to “normal” action. In the meantime, (a) you should consider keeping new buying light, and (b) take things on a stock-by-stock basis—if a name has shown great power and has consolidated (relatively) calmly for a couple of weeks, take a swing at it. Conversely, if something is sinking, honor your stop. Mike’s buy ideas today are: Fortinet (FTNT) and Inphi (IPHI). He has five sells today: Acadia Pharm (ACAD), InMode (INMD), Lennar (LEN), MasTec (MTZ) and Novocure (NVCR).

Weekly Issue December 9: The good news is that Mike continues to think current pullbacks and consolidations are leading to some good-looking entry points in a variety of leading stocks. All in all, he remains bullish, though it’s still best to be a bit choosier on the buy side at the moment, while giving some stocks that you own breathing room to consolidate if they’ve enjoyed a good run. This week’s list has many leaders that are retreating toward support or are otherwise showing solid setups. His Top Pick is Seattle Genetics (SGEN), which looks like a leader in the biotech field, and the stock is now pulling back for the first time after a big run.

Cabot Options Trader and Cabot Options Trader Pro

Note that the current week’s Weekly Update, earnings updates, position updates and stocks on watch are posted on the website in the Market Update section, which is deleted each week.
Cabot Options Trader Pro Alert December 13: Adjust Existing Position: Buy Back the Target (TGT) December 135 Call and Sell the January 135 Call (exp. 1/17/2020).

Cabot Options Trader Pro Alert December 12: Adjust Iron Condor: Buy back Half your Facebook (FB) December 215/220 Bear Call Spreads for $0.09 or less.

Cabot Options Trader Position Update December 12: Taiwan Semiconductor (TSM) is trading higher by another 3% today at 57.6. At these levels our April 55 Calls that were originally purchased for $2.40 could be sold for $4.70, or a potential profit of 95%. Jacob is going to continue to hold his position as the stock, and option activity remain wildly bullish.

Cabot Options Trader Stocks on Watch December 11: As the market awaits this afternoons Federal Reserve announcement on interest rates (no move expected), and likely more importantly the December 15th tariff deadline, Jacob wanted to highlight three interesting options trades made this morning, Luckin Coffee (LK), Peloton (PTON) and Anaplan (PLAN).

Cabot Options Trader Market Update December 10: As we get closer to December 15th, which is when a new round of tariffs are set to kick in, the rumors of a U.S./China deal being on/off are flying wildly. Unfortunately, Jacob expects this will continue in the days to come.

Cabot Options Trader Pro Weekly Update December 9: Jacob has 9 Long positions: BX, CRM, KO, JD, JBLU, LK, SNAP, TGT and TSM two short positions, SPY and FB.

Cabot Options Trader Weekly Update December 9: The Chicago Board of Options Exchange Volatility Index (VIX) closed the week at 13.6, or higher by 8%. Interestingly, the VIX spiked above 17 on Tuesday as the indexes came under pressure as trade tensions again seemed headed in a negative direction. However, by week’s end, as those tensions seemingly eased and following a “perfect” Jobs Report on Friday, the VIX was again signaling little fear of a large market decline.

Cabot Undervalued Stocks Advisor

Special Bulletin December 13: Adobe Systems (ADBE) reports good fourth-quarter results. Adobe Systems reported fourth-quarter and full-year results yesterday afternoon (November year end). The company achieved record quarterly and annual revenues of $2.99 billion and $11.17 billion, respectively. Non-GAAP diluted earnings per share came in at $2.29 vs. the $2.26 consensus estimate. The company also reported record cash flow. Also, they repurchased 2.8 million shares of stock during the quarter and 9.9 million shares during full-year 2019. It remains a Buy.

Special Bulletin December 10: Designer Brands (DBI) reported a disappointing third quarter this morning, in which gross margins were impacted by three non-recurring situations. Crista says that dividend investors and growth stock investors who like to buy bargains should buy now.

Weekly Update December 10: A high percentage of stocks that Crista follows are exhibiting bullish price charts right now. Obviously, you already knew that the stock market has been acting well. She simply wants to reiterate that the recent bullishness appears to be sustainable. Enjoy! Watch for earnings reports from Designer Brands (DBI) on Tuesday morning and Adobe Systems (ADBE) on Thursday afternoon. There are three portfolio changes today: Royal Caribbean (RCL) moves from Strong Buy to Sell, Tyson Foods (TSN) joins the Growth Portfolio as a Strong Buy and Universal Electronics (UEIC) moves from Hold to Buy.

Monthly Issue December 3: LGI Homes (LGIH) joins the Buy Low Opportunities Portfolio today and Quanta Services (PWR) rejoins the Growth Portfolio. Additionally, Crista says goodbye to CIT Group (CIT), which continues to have a slightly-improving price chart, but the 2020 earnings growth prospects are too dismal to remain in the Growth Portfolio. Other changes today are: Blackstone Group (BX) moves from Strong Buy to Hold and Universal Electronics (UEIC) moves from the Buy Low Opportunities Portfolio to the Growth Portfolio.

Cabot Stock of the Week

Weekly Issue December 10: The major indexes continue to hit new highs, all Cabot’s market timing indicators remain positive, and the portfolio is solid, overall, with the exception of Designer Brands (DBI), which reported third-quarter earnings this morning; Tim has more on that in the update section. Today’s new recommendation, Virgin Galactic (SPCE), is a brand new business with a familiar name—a high-risk/high-potential investment. It’s not for everyone, and it will be volatile. Tim has one rating change today: Designer Brands Inc. (DBI) moves from Buy to Hold.

Cabot Global Stocks Explorer

Bi-weekly Issue December 12: Because Carl missed an issue on Thanksgiving, today is a “catch-up” issue. The Cabot Global Stocks Explorer portfolio had another positive week led by last week’s recommendation, Virgin Galactic (SPCE), which is up 27% this week. Part of the reason is that Morgan Stanley picked up coverage of the stock with a 2020 price target of 22 – even higher than my price target of 20. Carl’s recommendation today is Freeport-McMoRan (FCX), headquartered in Phoenix, Arizona, it engages in the managing of mineral properties in North America, South America, and Indonesia. The company explores for copper, gold, molybdenum, silver, and other metals primarily in Indonesia as well as in Chile, Peru, New Mexico and Colorado. It is the world’s most significant copper producer. It’s rated Buy a Half.

Bi-weekly Issue December 5: As U.S. trade disputes spread to Latin America, Europe and a China deal may be pushed into 2020, markets struggled early in the week but rebounded yesterday. Hong Kong retail sales were hammered in October but China’s manufacturing finally turned upward. Our emerging market signal is positive with EEM trading just above its 50-day moving average. Carl will continue to diversify the portfolio and today rise above worldly concerns with a new recommendation that just may capture your imagination and make you money in 2020. Today’s featured stock is, Virgin Galactic (SPCE), a company that has been at the forefront of commercial space activity and produced the first private space vehicle to put humans into space. Carl has one portfolio change today: Huya (HUYA) moves from Hold a Half to Sell.

Cabot Small-Cap Confidential

Weekly Update December 13: The upward trajectory for growth stocks that was smooth sailing in November has turned far bumpier in December. Most of the stocks in our portfolio have lost some ground since last Thursday’s close. The big outlier was Domo (DOMO), which posted a snapback rally last Friday after reporting quarterly results. But double-digit declines in Construction Partners (ROAD), Cardlytics (CDLX) and our newest position, Health Catalyst (HCAT), along with modest declines in most of our software stocks, have offset that jump. Taken together, the evidence in front of Tyler says to be a little cautious here. He’s not reversing course on any stocks. But he does think that with a couple of wonky weeks on the horizon given the holiday schedule it’s probably a good time to do more watching than buying. He has no portfolio changes today.

Special Bulletin December 11: Construction Partners (ROAD) got knocked around pretty good yesterday but began to climb back in the afternoon and closed near 16. This wasn’t a blowout quarter by any stretch of the imagination. But does it mean the company is floundering? Tyler doesn’t think so. He believes there’s enough gas left in the tank here that small-cap funds will see this as a buying opportunity and continue to accumulate shares. He’s keeping at buy and will see what happens over the next week or so. BUY

Monthly Issue December 6: This month Tyler recommends a newly public company that’s trying to do what seems impossible – make the healthcare system work better. Health Catalyst (HCAT) is a $1.4 billion market cap company that provides cloud-based data and analytics technologies (55% of revenue) and professional services (45% of revenue) to healthcare organizations. There’s one portfolio change today: Veracyte (VCYT) moves from HOLD to BUY.

Cabot Dividend Investor

Weekly Update December 11: Tom likes the way the Cabot Dividend Investor portfolio is positioned right now. It has several REITs and Utilities that continue to benefit in the current environment, value stocks that offer bargains and new found momentum, and opportunities to benefit from strong growth where it is still powerful. He has one portfolio change today: Alexandria Real Estate Equities moves from Buy to Hold.

Monthly Issue November 26: The portfolio is still well positioned. It has a combination of defensive plays with renewed momentum as well as value stocks that are awakening. Since the last monthly issue, three weeks ago, the REIT and Utility sectors have regained their footing. The sectors had been the worst in the market over the past month as the renewed “risk on” mood shunned the more defensive plays. It remained a question whether the pullback was an overdue consolidation or a more meaningful correction. Recent behavior is indicating the latter. The notable exception to the value stock resurgence has been energy. Tom’s featured stock today is Qualcomm (QCOM), the world’s largest supplier of chips for mobile devices.

Cabot Marijuana Investor

Update December 11: The good news is that 2020 will bring great new opportunities for the industry, as Cannabis 2.0 kicks off in Canada and increasing numbers of U.S. operators take advantage of scale and experience to post real and growing earnings. The bad news is that the U.S. Federal government remains woefully behind the times, so true national operations are still a dream. But what we can do is invest in the greatest prospects, focusing on stocks that are not only above their mid-November lows but actually revealing true buying power, and if we don’t finish 2019 with a profit (it’s still very possible), the odds are quite good that—coming off this sector low—there will be big profits in 2020.

Monthly Issue November 27: The cannabis sector remains in a correction, with Canadian stocks in particular still struggling—even as Cannabis 2.0 promises new retail opportunities. But the fundamentals of the industry remain bright, and investors are now beginning to discriminate between the winners and the losers—with the best stocks showing substantial increases in buying volume recently. The portfolio remains more than a third in cash, waiting for the sector’s main trend to turn up, and Tim has just two small adjustments today. The portfolio will sell half its position in Cresco Labs (CRLBF) and double its position in Innovative Industrial Properties (IIPR).

Cabot Early Opportunities

Special Bulletin November 27: Small caps have been lagging, and have failed to return to their 2018 highs, for too long. If the asset class can get back in gear, Tyler will have more things working in the market for early-stage investors. Concurrently, he is seeing more strength in the IPO market too. The average gain across currently covered positions is 8%. That performance is twice what the broad market has delivered since we launched Cabot Early Opportunities in mid-September. So far, so good!

Monthly Issue November 20: In this Month’s Issue of Cabot Early Opportunities Tyler reveals a few tips to help you buy into IPOs at reasonable prices and he looks at some compelling data that suggests the 150 to 180 day period after IPO just might be one of the ideal times to buy. This month’s Top Pick is Livongo (LVGO), a $2.4 billion market cap company that specializes in Type 2 diabetes digital health management.

Bonus Report:

3 Cloud Software Stocks to Buy Now

Bonus Report:

3 Canadian Small-Cap Stocks to Buy Now

Bonus Report: Secrets To Early-Stage Stock Profits
Bonus Report:

The 240% Early-Stage Growth Stock

Cabot Profit Booster

Weekly Issue December 10: The Stock — Splunk (SPLK) Big data is big and growing bigger. The market is forecast to reach $103 billion by 2022, with every person generating 1.7 megabytes of data every second, with internet users as a whole expected to generate some 2.5 quintillion bytes of data each day. Suffice it to say, all this data has to be corralled and massaged into something useful, which is where Splunk makes its hay.

Bonus Report:

Best-Kept Hedge Fund Secrets to Explode Your Wealth

Bonus Report:

5 Easy Stock-Picking Secrets That Make it Ridiculously Easy to Profit.

Bonus Report:

The Simple Technique that Brings in 5%-15% Each Month.

Wall Street’s Best Investments

Daily Alert December 13: LGI Homes, Inc. (LGIH) Cabot Undervalued Stocks Advisor
Daily Alert December 12: Voya Financial, Inc. (VOYA-PB) Income Securities Investor
Daily Alert December 11: Nutanix, Inc. (NTNX) Pivotal Point
Daily Alert December 10: iShares Core Dividend Growth ETF (DGRO) Internet Wealth Builder
Daily Alert December 9: TopBuild Corp. (BLD) Upside

Monthly Issue November 20: So far, November’s markets have been a nice respite from the volatility of October, and the Dow Jones Industrial Average actually gained about 900 points. Investors—for the most part—seem to be ignoring China tariffs, impeachment hearings, and Brexit. And why not? After all, the economy remains strong and sentiment—as you’ll see in our Advisor Sentiment Barometer as well as in our Market Views—remains very bullish. Nancy begins this issue with CDW Corporation (CDW), a tech company that has successfully navigated the ever-changing technology world by adding new products—internally and by acquisition. Her feature article further explores the potential for this company to grab even more market share.

Ask the Experts

Cabot Options Trader

Question: Hi Jacob, so I have noticed that Mike is great at picking stocks that, as you say, accumulate, for a period and then often break out to the upside. He has had some phenomenal runners.Is the intent of the profit booster to collect option premium while price is accumulating(to the best that you can judge it? Obviously we don’t know when the accumulation will end). Once it breaks out, you are capping your profit by having sold the calls. Can you help me understand the rationale for what you are trying to achieve please?

Jacob: In essence we aren’t trying to hit grand slams with this strategy. Instead we are trying to hit singles and doubles over and over again. And while 3-15% a month profit on these trades doesn’t sound like a huge win, if you do this every month, you will be the greatest trader of all-time (yes I know occasionally these trades won’t work, so we won’t be take that title).Also, much like any portfolio, there should be a swing for the fences portion of the portfolio, and a safer portion. This would fall into the safer and yield creating category. And one last thing, Goldman Sachs just this week released an interesting chart showing the advantage of a buy-write when compared to the S&P 500 over the past 16 years.

Question: What is the difference between a covered call and a buy-write?

Jacob: Great question! Covered Calls and Buy-Writes are the same strategy, that go by two different names. It’s like pronouncing chowder and chowda’ .. same thing, just pronounced differently.

Cabot Dividend Investor

Question: I met you at the conference this summer. By the way I enjoyed your presentations and the delivery of same. I wanted your opinion on brk.b. Just hasn’t moved with the market and tons of cash. Thought it might be a sleeper out there.

Tom: Nice to hear from you. I hope all is well. The stock tends to mimic the moves of the overall market with less volatility. It plays it safer and has a ton of cash to invest in a down market, which makes it a good choice with the market at all time highs very late in the cycle. The drawbacks are that it is probably too big to deliver impressive returns and the stock will take a hit when Buffet leaves. In all, it’s not a bad pick but it won’t be great. Hope this helps.

Premium Reports

Quarterly Cabot Analyst Meeting

The recording of the quarterly Cabot Analyst Meeting from October 23, 2019 is now available for you to listen to at your convenience—click here for access. This quarterly private call with our analysts is one of your exclusive Cabot Prime Pro member benefits.

A Richer Retirement

Special Report This handbook is designed to help you secure a better, longer, richer retirement for yourself by making the most of your savings both before and during retirement.

Guide to Cabot Prime Pro

This Guide to Cabot Prime Pro will help you make the best use of your Prime membership to create a strong personal portfolio.

Stock Recommendations Tracker

The table below lists all of the stocks held in any Cabot portfolio.
Updated or revised recommendations from the past week are in purple text.
Stocks added to a portfolio are highlighted in green text.
Closed stock positions in the past week are highlighted in red text

StockCabot Small-Cap ConfidentialCabot Global Stocks ExplorerCabot Growth InvestorCabot Marijuana InvestorCabot Stock of the WeekCabot Undervalued Stocks AdvisorCabot Dividend Investor
ABBVBuy
ACBSee Advisory
ADBEBuy
ALXNStrong Buy
AMZNStrong Buy
ANFBuy
APHASee Advisory
APPFBuy
APPSHold
AREBuyHold
ARNABuy
AVLRBuy
BABABuy
BANDHold
BIPHoldHold
BKRBuy
BLDBuy
BMYHold
BSCJBuy 1/2
BSCLBuy 1/2
BXHold
CBuyBuy
CCIBuy
CDLXHold
CFStrong Buy
CGCSee Advisory
CHCTHold 1/3
CQPSold
CRAKStrong Buy
CRLBFSee Advisory
CRONSee Advisory
CTVABuyBuy
CURLFSee Advisory
DBIHoldStrong Buy
DBSDYBuy 1/2
DOCUBuy
DOMOHold
DOWBuy
DXCMHold
EPDBuyBuy
EQHStrong Buy
EVBGBuy
EVERHold
FCXBuy 1/2
GESStrong Buy
GSHDBuy
GTBIFSee Advisory
HCATBuy
HTHTHold
HUYASold
IBNBuy 1/2
IIPRSee Advisory
INSPBuy
IPHIBuyBuy
LGIHStrong Buy
LKBuy 1/2Buy
MCYBuy
MEDIFSee Advisory
MOBuy
MOSHold
MPCStrong Buy
MRVLBuy 1/2
MTHSold
MTZSell
NEEHoldHold 1/2
NVCRBuy 1/2
OGISee Advisory
OKTAHold
PDDHold
PGXBuy 1/2
PWRStrong Buy
QCOMBuy
QTRXHold 1/2
QRVOBuyBuy
QTWOBuy
RCLSell
RGENBuy
RIOBuy
RKUNYBuy 1/2
RNGHold
ROADBuy
RPDBuy
SEBuy 1/2
SLBBuy
SNAPHold
SPCEBuy a HalfBuy
SSOBuy
STAGHold
TCNNFSee AdvisoryBuy
TDOCBuy
TOTBuy
TPBSee Advisory
TSLAHold
TSNStrong Buy
TVBuy 1/2
UEICBuy
VCYTBuy
VLOBuy
VOYAStrong Buy
VRTXBuy
XELHold 2/3